In vitro and in vivo evaluation of synergism between anti-tubercular spectinamides and non-classical tuberculosis antibiotics

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Bruhn, David F ^a   Scherman, Michael S ^a   Liu, Jiuyu ^a   Scherbakov, Dimitri ^c   Meibohm, Bernd ^d   Böttger, Erik C ^c   Lenaerts, Anne J ^b   Lee, Richard E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Veterinary Dentistry and Oral Surgery   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; TUBERCULOSTATIC AGENT;

ACUTE DISEASE; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; HALF LIFE TIME; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

ACUTE DISEASE; ANIMALS; ANTITUBERCULAR AGENTS; CLARITHROMYCIN; CLINDAMYCIN; DISEASE MODELS, ANIMAL; DOXYCYCLINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HALF-LIFE; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84941629631     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13985     Document Type: Article

References (57)

1. Zumla, A., Raviglione, M., Hafner, R. & von Reyn, C. F. Tuberculosis. N Engl J Med 368, 745-755, doi: 10.1056/NEJMra1200894 (2013).
2. CDC. Trends in Tuberculosis, 2013. (U.S. Department of Health and Human Services Centers for Disease Control and Prevention, 2013).
3. Mattila, J. T., et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 191, 773-784, doi: 10.4049/jimmunol.1300113 (2013).
4. Gupta, A., Kaul, A., Tsolaki, A. G., Kishore, U. & Bhakta, S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 217, 363-374, doi: 10.1016/j.imbio.2011.07.008 (2012).
5. Adams, K. N., et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145, 39-53, doi: 10.1016/j.cell.2011.02.022 (2011).
6. Ramakrishnan, L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12, 352-366, doi: 10.1038/nri3211 (2012).
7. Gunther, G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med 14, 279-285, doi: 10.7861/clinmedicine.14-3-279 (2014).
8. CDC. Impact of a Shortage of First-Line Antituberculosis Medication on Tuberculosis Control - United States, 2012-2013. (U.S. Department of Health and Human Services Centers for Disease Control and Prevention, 2013).
9. Pasipanodya, J. G., et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208, 1464-1473, doi: 10.1093/infdis/jit352 (2013).
10. Bottger, E. C., Springer, B., Pletschette, M. & Sander, P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 4, 1343-1344, doi: 10.1038/3906 (1998).
11. Sander, P., et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 46, 1204-1211 (2002).
12. Meyer, M., et al. In vivo efficacy of apramycin in murine infection models. Antimicrob Agents Chemother 58, 6938-6941, doi: 10.1128/AAC.03239-14 (2014).
13. Matt, T., et al. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci USA 109, 10984-10989, doi: 10.1073/pnas.1204073109 (2012).
14. Stover, C. K., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966, doi: 10.1038/35016103 (2000).
15. Matsumoto, M., et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3, e466, doi: 10.1371/journal.pmed.0030466 (2006).
16. Diacon, A. H., et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56, 3271-3276, doi: 10.1128/AAC.06126-11 (2012).
17. Protopopova, M., et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56, 968-974, doi: 10.1093/jac/dki319 (2005).
18. Upton, A. M., et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 59, 136-144, doi: 10.1128/AAC.03823-14 (2015).
19. Louw, G. E., et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 184, 269-276, doi: 10.1164/rccm.201011-1924OC (2011).
20. Gupta, S., et al. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 188, 600-607, doi: 10.1164/rccm.201304-0650OC (2013).
21. Lee, R. E., et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med, doi: 10.1038/nm.3458 (2014).
22. Carter, A. P., et al. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407, 340-348, doi: 10.1038/35030019 (2000).
23. Duscha, S., et al. Identification and evaluation of improved 4? -O-(alkyl) 4,5-disubstituted 2-deoxystreptamines as next-generation aminoglycoside antibiotics. mBio 5, e01827-01814, doi: 10.1128/mBio.01827-14 (2014).
24. Hobbie, S. N., et al. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA 105, 20888-20893, doi: 10.1073/pnas.0811258106 (2008).
25. Perez-Fernandez, D., et al. 4′-O-substitutions determine selectivity of aminoglycoside antibiotics. Nat Commun 5, 3112, doi: 10.1038/ncomms4112 (2014).
26. Walter, N. D., et al. Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis during treatment of human tuberculosis. J Infect Dis, doi: 10.1093/infdis/jiv149 (2015).
27. Balganesh, M., et al. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob Agents Chemother 56, 2643-2651, doi: 10.1128/AAC.06003-11 (2012).
28. Ramon-Garcia, S., et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. Antimicrob Agents Chemother 55, 3861-3869, doi: 10.1128/AAC.00474-11 (2011).
29. Bauer, G., Berens, C., Projan, S. J. & Hillen, W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 53, 592-599, doi: 10.1093/jac/dkh125 (2004).
30. Chu, S. Y., et al. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother 36, 2447-2453 (1992).
31. Mazur, D., et al. Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation. Int J Clin Pharmacol Ther 37, 386-392 (1999).
32. Malmborg, A. S. Bioavailability of doxycycline monohydrate. A comparison with equivalent doses of doxycycline hydrochloride. Chemotherapy 30, 76-80 (1984).
33. Sjolin-Forsberg, G. & Hermansson, J. Comparative bioavailability of tetracycline and lymecycline. Br J Clin Pharmacol 18, 529-533 (1984).
34. Luna-Herrera, J., Reddy, V. M., Daneluzzi, D. & Gangadharam, P. R. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 39, 2692-2695 (1995).
35. Lenaerts, A. J., et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49, 2294-2301, doi: 10.1128/AAC.49.6.2294-2301.2005 (2005).
36. Lenaerts, A. J., Degroote, M. A. & Orme, I. M. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol 16, 48-54, doi: 10.1016/j.tim.2007.12.002 (2008).
37. Hoffman, H. L., et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 47, 739-746 (2003).
38. Canu, A. & Leclercq, R. Overcoming bacterial resistance by dual target inhibition: the case of streptogramins. Curr Drug Target Infect Disord 1, 215-225 (2001).
39. Drusano, G. L., et al. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. mBio 1, doi: 10.1128/mBio.00139-10 (2010).
40. Seung, K. J., et al. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect 20, 441-446, doi: 10.1111/1469- 0691.12335 (2014).
41. Dooley, K. E., et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 207, 1352-1358, doi: 10.1093/infdis/jis460 (2013).
42. Caminero, J. A., Sotgiu, G., Zumla, A. & Migliori, G. B. Best drug treatment for multidrug-resistant and extensively drugresistant tuberculosis. Lancet Infect Dis 10, 621-629, doi: 10.1016/S1473-3099(10)70139-0 (2010).
43. Bolhuis, M. S., et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 42, 1614-1621, doi: 10.1183/09031936.00001913 (2013).
44. Falzari, K., et al. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 49, 1447-1454, doi: 10.1128/AAC.49.4.1447-1454.2005 (2005).
45. Dartois, V. & Barry, C. E., 3rd. A medicinal chemists guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 23, 4741-4750, doi: 10.1016/j.bmcl.2013.07.006 (2013).
46. Lenaerts, A. J., Gruppo, V., Brooks, J. V. & Orme, I. M. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 47, 783-785 (2003).
47. Hoogeterp, J. J., Mattie, H. & van Furth, R. Activity of erythromycin and clindamycin in an experimental Staphylococcus aureus infection in normal and granulocytopenic mice. A comparative in vivo and in vitro study. Scand J Infect Dis 25, 123-132 (1993).
48. Joiner, K. A., Lowe, B. R., Dzink, J. L. & Bartlett, J. G. Antibiotic levels in infected and sterile subcutaneous abscesses in mice. J Infect Dis 143, 487-494 (1981).
49. Fernandes, P. B., Hardy, D. J., McDaniel, D., Hanson, C. W. & Swanson, R. N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 33, 1531-1534 (1989).
50. Vallee, E., Azoulay-Dupuis, E., Swanson, R., Bergogne-Berezin, E. & Pocidalo, J. J. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. J Antimicrob Chemother 27 Suppl A, 31-41 (1991).
51. Zeidner, N. S., et al. Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis. Antimicrob Agents Chemother 48, 2697-2699, doi: 10.1128/AAC.48.7.2697-2699.2004 (2004).
52. Lee, J. & Wormser, G. P. Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Int J Antimicrob Agents 31, 235-239, doi: 10.1016/j.ijantimicag.2007.11.011 (2008).
53. Vicente, E., et al. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrob Agents Chemother 52, 3321-3326, doi: 10.1128/AAC.00379-08 (2008).
54. Lenaerts, A. J., Degroote, M. A. & Orme, I. M. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol 16, 48-54, doi: 10.1016/j.tim.2007.12.002 (2008).
55. De Groote, M. A., et al. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrobial Agents Chemother 55, 1237-1247, doi: 10.1128/AAC.00595-10 (2011).
56. De Groote, M. A., et al. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis. Antimicrobial Agents Chemother 56, 731-738, doi: 10.1128/AAC.05701-11 (2012).
57. Salian, S., et al. Structure-activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups. Antimicrob Agents Chemother 56, 6104-6108, doi: 10.1128/AAC.01326-12 (2012).